Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Combe

Showing results (121-130 of 282) with videos related to

Pageof 29
Sort By:
Arthritis Research & Therapy|November 28, 2014
Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE studyMaxime Dougados, Emily Wood, Bernard Combe, et al.
Rheumatology (Oxford, England)|August 12, 2021
CXCR5/CXCL13 pathway, a key driver for migration of regulatory B10 cells, is defective in patients with rheumatoid arthritisClaire Rempenault, Julie Mielle, Kristina Schreiber, et al.
Arthritis Research & Therapy|January 4, 2022
The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studiesClifton O Bingham, David Walker, Peter Nash, et al.
Arthritis Care & Research|November 12, 2014
Evaluation of serum interleukin-6 level as a surrogate marker of synovial inflammation and as a factor of structural progression in early rheumatoid arthritis: results from a French national multicenter cohortAthan Baillet, Laure Gossec, Simon Paternotte, et al.
BMC Musculoskeletal Disorders|September 12, 2012
Rheumatoid arthritis and sexuality: a patient survey in FranceGisela Kobelt, Brigitte Texier-Richard, Sylvain Mimoun, et al.
Rheumatology (Oxford, England)|November 26, 2009
Early referral to the rheumatologist for early arthritis patients: evidence for suboptimal care. Results from the ESPOIR cohortBruno Fautrel, Mathilde Benhamou, Violaine Foltz, et al.
RMD Open|January 21, 2020
Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational studyAlain Saraux, René-Marc Flipo, Francis Fagnani, et al.
The Journal of Rheumatology|January 18, 2011
Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysisRobert Launois, Bernard Avouac, Francis Berenbaum, et al.
Joint Bone Spine|December 1, 2009
Non-drug treatment (excluding surgery) in rheumatoid arthritis: clinical practice guidelinesRomain Forestier, Joëlle André-Vert, Pascal Guillez, et al.
Annals of the Rheumatic Diseases|February 9, 2013
Defining erosive disease typical of RA in the light of the ACR/EULAR 2010 criteria for rheumatoid arthritis; results of the data driven phaseRachel Knevel, Cédric Lukas, Désirée van der Heijde, et al.
Pageof 29

Showing results (121-130 of 282) with videos related to

Sort By:
Pageof 29
Arthritis Research & Therapy|November 28, 2014
Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE studyMaxime Dougados, Emily Wood, Bernard Combe, et al.
Rheumatology (Oxford, England)|August 12, 2021
CXCR5/CXCL13 pathway, a key driver for migration of regulatory B10 cells, is defective in patients with rheumatoid arthritisClaire Rempenault, Julie Mielle, Kristina Schreiber, et al.
Arthritis Research & Therapy|January 4, 2022
The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studiesClifton O Bingham, David Walker, Peter Nash, et al.
Arthritis Care & Research|November 12, 2014
Evaluation of serum interleukin-6 level as a surrogate marker of synovial inflammation and as a factor of structural progression in early rheumatoid arthritis: results from a French national multicenter cohortAthan Baillet, Laure Gossec, Simon Paternotte, et al.
BMC Musculoskeletal Disorders|September 12, 2012
Rheumatoid arthritis and sexuality: a patient survey in FranceGisela Kobelt, Brigitte Texier-Richard, Sylvain Mimoun, et al.
Rheumatology (Oxford, England)|November 26, 2009
Early referral to the rheumatologist for early arthritis patients: evidence for suboptimal care. Results from the ESPOIR cohortBruno Fautrel, Mathilde Benhamou, Violaine Foltz, et al.
RMD Open|January 21, 2020
Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational studyAlain Saraux, René-Marc Flipo, Francis Fagnani, et al.
The Journal of Rheumatology|January 18, 2011
Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysisRobert Launois, Bernard Avouac, Francis Berenbaum, et al.
Joint Bone Spine|December 1, 2009
Non-drug treatment (excluding surgery) in rheumatoid arthritis: clinical practice guidelinesRomain Forestier, Joëlle André-Vert, Pascal Guillez, et al.
Annals of the Rheumatic Diseases|February 9, 2013
Defining erosive disease typical of RA in the light of the ACR/EULAR 2010 criteria for rheumatoid arthritis; results of the data driven phaseRachel Knevel, Cédric Lukas, Désirée van der Heijde, et al.
Pageof 29